Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 3.52 USD 0.28% Market Closed
Market Cap: $1.1B

Abcellera Biologics Inc
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Abcellera Biologics Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Goodwill
$47.8m
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abcellera Biologics Inc
Glance View

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

ABCL Intrinsic Value
1.52 USD
Overvaluation 57%
Intrinsic Value
Price $3.52

See Also

What is Abcellera Biologics Inc's Goodwill?
Goodwill
47.8m USD

Based on the financial report for Dec 31, 2025, Abcellera Biologics Inc's Goodwill amounts to 47.8m USD.

What is Abcellera Biologics Inc's Goodwill growth rate?
Goodwill CAGR 5Y
9%

Over the last year, the Goodwill growth was 0%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett